[1. Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia kliniczna. Tom 2. 3rd ed. Gdańsk: Via Medica; 2015.]Search in Google Scholar
[2. Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4:173-85.10.21037/atm.2016.03.34]Search in Google Scholar
[3. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829.10.1172/jci.insight.89829]Search in Google Scholar
[4. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 2014;26:123-41.10.1016/j.coms.2014.01.001]Search in Google Scholar
[5. Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immuno-therapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015;36:587-95.10.1016/j.tips.2015.06.005]Search in Google Scholar
[6. De Costa A-MA, Young MRI. Immunotherapy for head and neck cancer: advances and deficiencies. Anti-Cancer Drugs 2011;22:674-81.10.1097/CAD.0b013e328340fd18]Search in Google Scholar
[7. Grzywnowicz M, Giannopoulos K. Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. Acta Haematologica Polonica 2012;43:132-45.10.1016/S0001-5814(12)32008-2]Search in Google Scholar
[8. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293-304.10.1200/JCO.2015.61.1509458616926351330]Search in Google Scholar
[9. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA – 4 with ipilimumab (MDX-010). Oncologist 2008;13(Suppl 4):16-25.10.1634/theoncologist.13-S4-1619001147]Search in Google Scholar
[10. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010;363:711-23.10.1056/NEJMoa1003466354929720525992]Search in Google Scholar
[11. Argiris A, Gillison M, Ferris RL, Harrington K, Sanchez TK, Baudelet C, et al. A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cel carcinoma of the head and neck – CheckMate 651. Ann Oncol 2016;27(Suppl 6):328-50.10.1093/annonc/mdw376.68]Search in Google Scholar
[12. Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer 2017;8:410-6.10.7150/jca.17144]Search in Google Scholar
[13. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67.10.1056/NEJMoa1602252]Search in Google Scholar
[14. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Anti-tumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 2016;34:3838-45.10.1200/JCO.2016.68.1478]Search in Google Scholar
[15. Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Abstract LBA45_PR „Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial”. Zaprezentowano przez Cohen EE. ESMO 2017 Congress, Lugano-Madryt.10.1093/annonc/mdx440.040]Search in Google Scholar
[16. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.10.1200/JCO.2006.06.7447]Search in Google Scholar
[17. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.10.1056/NEJMoa0802656]Search in Google Scholar
[18. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. Lancet Oncol 2015;16: 583-94.10.1016/S1470-2045(15)70124-5]Search in Google Scholar